Tarek Haykal, MD

In this segment, our panel walks through the initial workup for a patient newly diagnosed with uveal melanoma, with a focus on how gene expression profiling and PRAME status are used to stratify patients by metastatic risk.

In this segment, our panel establishes why uveal melanoma is a fundamentally different disease from cutaneous melanoma and why that distinction matters for every treatment decision that follows.